Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-11-13Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002) [Phase 1]
Phase 1 clinical trial updating safety, tolerability, pharmacokinetics and pharmacodynamics of MK-8655 in adults with Type 2 Diabetes; compl…
-
CLINICAL_TRIALS trial_result · 2018-11-08Clinical Trial Update: Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"
Clinical trial update for alogliptin tablets investigating monotherapy and combination therapy with alpha-glucosidase inhibitor in type 2 di…
-
CLINICAL_TRIALS trial_result · 2018-11-08Clinical Trial Update: Home Exercise to Enhance Mobility for Older Diabetics [NA]
A completed clinical trial evaluating home exercise to improve mobility in adults with type 2 diabetes; results posted in 2018.
-
FDA label_change · 2018-11-07FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Oceanside Pharmaceuticals)
The FDA has approved a supplemental application for metformin hydrochloride filed by Oceanside Pharmaceuticals. The submission status is AP.
-
CLINICAL_TRIALS trial_result · 2018-11-07Clinical Trial Update: Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients [NA]
A completed study comparing the Finesse insulin dosing device to traditional insulin pens for initiating bolus insulin in adults with Type 2…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-11-07Clinical Trial Update: Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040) [Phase 1]
Phase 1 trial update evaluating once vs twice daily dosing of ertugliflozin (MK-8835) in adults with type 2 diabetes; results completed with…
-
FDA approval · 2018-11-06FDA Approved: HUMULIN 70/30 — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Humulin 70/30 (insulin human) from Eli Lilly and Company.
-
FDA approval · 2018-11-06FDA Approved: RIOMET — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a Sun Pharmaceutical supplemental application for RIOMET (metformin hydrochloride), updating the product's regulatory status.
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide [Phase 3]
A Phase 3 trial evaluating safety and tolerability of switching to ITCA 650 in patients with type 2 diabetes currently receiving liraglutide…
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: Basal Insulin Strategies Before Surgery [NA]
A completed clinical trial evaluated basal insulin strategies before surgery in type 2 diabetes mellitus; results were posted in 2018.
-
FDA approval · 2018-11-02FDA Approved: METFORMIN — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approval of Ingenus Pharmaceuticals' generic metformin (METFORMIN) under an original ANDA, expanding access to metformin tablets for typ…
-
FDA approval · 2018-11-01FDA Approved: INSULIN LISPRO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for INSULIN LISPRO submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2018-11-01Clinical Trial Update: A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics [Phase 1]
Phase 1 study comparing insulin peglispro and glargine in type 2 diabetes completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-11-01Clinical Trial Update: PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients [Phase 1]
Phase 1 multiple ascending dose study of PF-06291874 in adults with type 2 diabetes completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2018-10-31Clinical Trial Update: A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes [Phase 3]
A Phase 3 trial evaluating the effect of dapagliflozin on blood glucose and renal safety in adults with Type 2 diabetes completed with poste…
-
CLINICAL_TRIALS trial_result · 2018-10-30Clinical Trial Update: Linagliptin Inpatient Trial [Phase 4]
Phase 4 inpatient trial of linagliptin for type 2 diabetes has completed, with results posted on 2018-10-30. The study was sponsored by Emor…
-
FDA label_change · 2018-10-29FDA Approved: INVOKANA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKANA (canagliflozin) from Janssen Pharmaceuticals, Inc. to update the drug's labeling.
-
FDA approval · 2018-10-29FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET (canagliflozin and metformin hydrochloride) from Janssen Pharmaceuticals, Inc. The…
-
FDA approval · 2018-10-29FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin HCl) from Janssen Pharmaceuticals, Inc. under NDA 2058…
-
FDA approval · 2018-10-26FDA Approved: SEGLUROMET — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Segluromet (ertugliflozin and metformin hydrochloride) from Merck Sharp & Dohme LLC. The action …
-
FDA approval · 2018-10-26FDA Approved: INVOKANA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA has approved a supplemental application for INVOKANA (canagliflozin) submitted by Janssen Pharmaceuticals, Inc. The approval updates…
-
FDA approval · 2018-10-26FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET, a fixed-dose combination of canagliflozin and metformin hydrochloride, submitted …
-
FDA approval · 2018-10-26FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Dapagliflozin and Metformin Hydrochloride (Prasco Laboratories), expanding the label for this co…
-
FDA approval · 2018-10-26FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin hydrochloride) submitted by Janssen Pharmaceutical…
-
FDA approval · 2018-10-26FDA Approved: STEGLATRO — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for STEGLATRO (ertugliflozin) from Merck Sharp & Dohme LLC.